AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
February 16, 2021
Ryan Allway February 16th, 2021 Psychedelics, Top News NEW YORK, Feb. 16, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the execution of a Letter of Intent with Silo Pharma Inc. (“Silo”) to grant to AIkido a worldwide, exclusive sublicense for use of peptide therapy, combined with psilocybin, in the therapeutic... Read more
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
February 12, 2021
Ryan Allway February 12th, 2021 Psychedelics Revive Therapeutics Ltd. (“Revive”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000... Read more
Cybin to Provide Business Update on February 17, 2021 Conference Call
February 11, 2021
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
February 5, 2021
Toronto, Ontario–(Newsfile Corp. – February 5, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset” or the “Company“), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce that the Company has filed 3 final patent applications... Read more
Ryan Allway February 4th, 2021 Psychedelics Earlier today the TGA announced its interim decision not to amend the current Poisons Standard in relation to the use of medical grade psilocybin and medical grade MDMA as part of therapy to treat patients suffering from treatment resistant mental illnesses including Depression,... Read more
Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol
February 4, 2021
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Ryan Allway February 4th, 2021 Psychedelics Dr. Roger McIntyre, Chairman of the Board of Directors of Champignon Brands Inc. today announces changes to the Champignon Board of Directors (“Champignon“) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF). Bill Wilkerson, LL. D. (Hon), appointed to the Board of Directors of Champignon on... Read more
Better Plant’s Jusu Begins Expansion into U.S. Market
February 4, 2021
Ryan Allway February 4th, 2021 Psychedelics Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce it has engaged the Thank You Merci’s sales and merchandising team (“TYM“) to represent Jusu Body, Jusu Life, and Jusu Juice; commencing immediately. TYM offers full-service sales... Read more
PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease
February 4, 2021
Ryan Allway February 4th, 2021 Psychedelics Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, announced today the successful completion of a Type B pre-Investigational New Drug (“pre-IND”)... Read more
Ryan Allway February 3rd, 2021 Psychedelics Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management,... Read more
